The CLARICOR Trial: Effect of Clarithromycin on Mortality and Morbidity in Patients With Ischemic Heart Disease
Heart Disease, Cardiovascular Disease
About this trial
This is an interventional treatment trial for Heart Disease focused on measuring Coronary heart disease, Clarithromycin, Macrolides, Cardiovascular mortality, Chlamydia pneumoniae
Eligibility Criteria
Inclusion Criteria: patients aged 18 to 85 years and previous acute myocardial infarction (AMI) or previous or present angina pectoris and signed informed concent Exclusion Criteria: AMI or unstable angina pectoris within the last three months revascularisation (PTCA or CABG) within the preceding six months severe heart failure (New York Heart Association (NYHA) functional class IV) known impaired renal or hepatic function active malignancy intolerance to macrolides treatment with methylxanthines, carbamazepine, cisapride, astemizole, terfenadine, or coumarin anticoagulants earlier inclusion in the CLARICOR Trial or participation in another drug trial within four weeks participation in other clinical trials within one month before this trial individuals incapable of managing own affairs or not able to sign written consent lack of written consent women of childbearing age not using reliable contraceptives breast feeding women
Sites / Locations
- Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9
- H:S Rigshospitalet
- H:S Amager Hospital
- H:S Bispebjerg Hospital
- H:S Frederiksberg Hospital
- H:S Hvidovre Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Clarithromycin
Placebo
Clarithromycin is a lipophilic semi-synthetic macrolide antibiotic. The lipophilic nature of the drug allows it to easily penetrate into body fluids and tissues and accumulate intracellularly. Side effects are few, apart from trivial gastrointestinal complaints, and severe side effects are rarely observed during standard treatment.
Placebo comparator